Articles with public access mandates - Tawee TanvetyanonLearn more
Not available anywhere: 1
Dose-limiting pulmonary toxicity in a phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for patients with stage 3 Unresectable Non-small Cell …
CL Liveringhouse, K Latifi, AG Asous, NB Lam, SA Rosenberg, TJ Dilling, ...
International Journal of Radiation Oncology* Biology* Physics 116 (4), 837-848, 2023
Mandates: US National Institutes of Health
Available somewhere: 24
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
BC Creelan, C Wang, JK Teer, EM Toloza, J Yao, S Kim, AM Landin, ...
Nature medicine 27 (8), 1410-1418, 2021
Mandates: US National Institutes of Health, V Foundation, USA
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non–small-cell lung cancer
EB Haura, T Tanvetyanon, A Chiappori, C Williams, G Simon, S Antonia, ...
Journal of Clinical Oncology 28 (8), 1387-1394, 2010
Mandates: US National Institutes of Health
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements
DN Hayes, AS Lucas, T Tanvetyanon, MK Krzyzanowska, CH Chung, ...
Clinical Cancer Research 18 (7), 2056-2065, 2012
Mandates: US National Institutes of Health
Randomized international phase III trial of ERCC1 and RRM1 expression–based chemotherapy versus gemcitabine/carboplatin in advanced non–small-cell lung cancer
G Bepler, C Williams, MJ Schell, W Chen, Z Zheng, G Simon, S Gadgeel, ...
Journal of Clinical Oncology 31 (19), 2404-2412, 2013
Mandates: US National Institutes of Health
Smoking cessation, version 1.2016, NCCN clinical practice guidelines in oncology
PG Shields, RS Herbst, D Arenberg, NL Benowitz, L Bierut, JB Luckart, ...
Journal of the National Comprehensive Cancer Network 14 (11), 1430-1468, 2016
Mandates: US National Institutes of Health
Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer
G Bepler, KE Sommers, A Cantor, X Li, A Sharma, C Williams, ...
Journal of Thoracic Oncology 3 (10), 1112-1118, 2008
Mandates: US National Institutes of Health
Phase I/Ib study of pembrolizumab plus vorinostat in advanced/metastatic non–small cell lung cancer
JE Gray, A Saltos, T Tanvetyanon, EB Haura, B Creelan, SJ Antonia, ...
Clinical Cancer Research 25 (22), 6623-6632, 2019
Mandates: US National Institutes of Health
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors
SJ Wong, T Karrison, DN Hayes, MS Kies, KJ Cullen, T Tanvetyanon, ...
Annals of oncology 27 (2), 318-323, 2016
Mandates: US National Institutes of Health
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings
V Kumar, K Nath, CG Berman, J Kim, T Tanvetyanon, AA Chiappori, ...
Clinical nuclear medicine 38 (3), 175-182, 2013
Mandates: US National Institutes of Health
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors
JE Gray, E Haura, A Chiappori, T Tanvetyanon, CC Williams, ...
Clinical Cancer Research 20 (6), 1644-1655, 2014
Mandates: US National Institutes of Health
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
J Gilbert, MJ Schell, X Zhao, B Murphy, T Tanvetyanon, ME Leon, ...
Oral oncology 51 (4), 376-382, 2015
Mandates: US National Institutes of Health
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with …
AA Chiappori, CC Williams, JE Gray, T Tanvetyanon, EB Haura, ...
Cancer Immunology, Immunotherapy 68, 517-527, 2019
Mandates: US National Institutes of Health
Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
BC Creelan, DI Gabrilovich, JE Gray, CC Williams, T Tanvetyanon, ...
OncoTargets and therapy, 4239-4250, 2017
Mandates: US National Institutes of Health
Relationship of exercise to quality of life in cancer patients beginning chemotherapy
LA Faul, HS Jim, S Minton, M Fishman, T Tanvetyanon, PB Jacobsen
Journal of pain and symptom management 41 (5), 859-869, 2011
Mandates: US National Institutes of Health
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell–based vaccine for refractory lung adenocarcinoma
BC Creelan, S Antonia, D Noyes, TB Hunter, GR Simon, G Bepler, ...
Journal of Immunotherapy 36 (8), 442-450, 2013
Mandates: US National Institutes of Health
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
MG Fury, E Sherman, D Lisa, N Agarwal, K Algazy, B Brockstein, ...
Journal of the National Comprehensive Cancer Network 10 (11), 1391-1398, 2012
Mandates: US National Institutes of Health
Phase I study of Taminadenant (PBF509/NIR178), an Adenosine 2A receptor antagonist, with or without Spartalizumab (PDR001), in patients with Advanced non–small cell Lung Cancer
AA Chiappori, B Creelan, T Tanvetyanon, JE Gray, EB Haura, R Thapa, ...
Clinical Cancer Research 28 (11), 2313-2320, 2022
Mandates: US National Institutes of Health
Prospective single-arm phase 1 and 2 study: ipilimumab and nivolumab with thoracic radiation therapy after platinum chemotherapy in extensive-stage small cell lung cancer
BA Perez, S Kim, M Wang, AM Karimi, C Powell, J Li, TJ Dilling, ...
International Journal of Radiation Oncology* Biology* Physics 109 (2), 425-435, 2021
Mandates: US National Institutes of Health
A phase I/randomized phase II study of GM. CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma
JE Gray, A Chiappori, CC Williams, T Tanvetyanon, EB Haura, ...
Cancer Immunology, Immunotherapy 67, 1853-1862, 2018
Mandates: US National Institutes of Health, Florida Department of Health, USA
Publication and funding information is determined automatically by a computer program